Is it safe for a patient who uses cannabis daily to take Auvelity (dextromethorphan/bupropion) for treatment‑resistant depression?

Cannabis Use with Auvelity: Exercise Extreme Caution

Patients using cannabis daily should avoid Auvelity (dextromethorphan/bupropion) or proceed with extreme caution under close monitoring, as the FDA label explicitly warns against concurrent use of "street (illicit) drugs" and the combination may worsen mood during cannabis withdrawal. 1

Critical Safety Concerns from FDA Labeling

The Auvelity prescribing information specifically instructs patients to inform their healthcare provider if they "abuse prescription medicines or street drugs" and lists "street (illicit) drugs" among medications requiring special consideration. 1 This is particularly relevant given that:

• Cannabis remains federally classified as a Schedule I controlled substance, making it technically an illicit drug from a federal regulatory perspective 2
• Bupropion (one of Auvelity's components) has been shown to worsen mood during marijuana withdrawal, significantly increasing ratings of irritability, restlessness, depression, and trouble sleeping compared to placebo 3

Mechanism-Based Risks

Drug Interaction Concerns

Cannabis interacts with multiple cytochrome P450 enzymes (including CYP2C9, CYP2C19, and CYP3A4), creating potential for altered drug metabolism. 2 While bupropion primarily inhibits CYP2D6 to increase dextromethorphan levels, the complex pharmacokinetic interactions with cannabis remain poorly characterized. 2

The ASCO guideline specifically identifies bupropion as having "high risk" for drug-drug interactions with cannabis, though the exact clinical implications for the dextromethorphan/bupropion combination are not well-studied. 2

Neuropsychiatric Risks

Both cannabis and Auvelity carry independent neuropsychiatric risks that may be additive or synergistic:

• Cannabis use is associated with major depression, suicidal ideation, anxiety, and psychotic symptoms, particularly with heavy use 4
• Auvelity carries FDA black box warnings for increased suicidal thoughts and actions, especially in young adults during initial treatment 1
• Auvelity can cause manic episodes in patients with bipolar disorder, and cannabis use may unmask or exacerbate bipolar symptoms 4, 1

Cardiovascular Considerations

Both cannabis and Auvelity independently increase cardiovascular risks:

• Cannabis smoking is associated with myocardial infarction, stroke, and arrhythmias 4
• Auvelity can cause hypertension requiring blood pressure monitoring 1
• The combination may produce additive cardiovascular stress 4, 1

Seizure Risk Amplification

This represents perhaps the most serious concern:

• Auvelity is absolutely contraindicated in patients with seizure disorders and carries significant seizure risk, particularly at higher doses 1
• Cannabis use may lower seizure threshold in susceptible individuals 4
• Sudden cannabis cessation after daily use can precipitate seizures, similar to alcohol withdrawal 1

Clinical Decision Algorithm

If Patient Is Currently Using Cannabis Daily:

1. Assess cannabis use pattern: Quantify daily intake (grams/day or mg THC/day), duration of use, and screen for cannabis use disorder 5

2. Evaluate for contraindications: Screen for seizure history, eating disorders, bipolar disorder, cardiovascular disease, and psychotic symptoms 1

3. Consider alternative antidepressants first: Given the documented worsening of mood during cannabis withdrawal with bupropion, other antidepressant classes (SSRIs, SNRIs) may be safer initial choices 3

4. If Auvelity is deemed necessary:

   • Do NOT attempt rapid cannabis cessation due to seizure and mood destabilization risks 1, 3
   • Consider gradual cannabis taper over ≥7 days if patient is motivated and surgery/urgent treatment is not required 5
   • Start with lowest Auvelity dose (one tablet daily) and monitor closely 1
   • Implement intensive monitoring: weekly visits initially, blood pressure checks, mood/suicidality assessment 1
   • Counsel patient to avoid alcohol, which further increases seizure risk 1

5. Monitor for warning signs:

   • Worsening depression, irritability, or suicidal ideation (particularly in first 2 weeks) 1, 3
   • Manic symptoms (increased energy, racing thoughts, reckless behavior) 1
   • Cardiovascular symptoms (chest pain, palpitations, severe hypertension) 4, 1
   • Any seizure activity (immediate discontinuation required) 1

Special Populations

Patients with treatment-resistant depression: While Auvelity shows promise for treatment-resistant depression 6, 7, 8, 9, the combination with daily cannabis use creates unacceptable risk without clear evidence of benefit. Consider other evidence-based options for treatment-resistant depression (ketamine/esketamine, ECT, TMS) that may have better-characterized interactions with cannabis. 10

Patients using cannabis for medical reasons: If cannabis is being used to manage symptoms like chronic pain, nausea, or anxiety, address these underlying conditions with alternative evidence-based treatments before initiating Auvelity. 2

Bottom Line

The safest approach is to avoid combining daily cannabis use with Auvelity. If treatment with Auvelity is essential, cannabis should ideally be discontinued with gradual taper (not abrupt cessation) under close medical supervision, waiting at least 7 days after cessation before initiating Auvelity. 5, 3 The documented mood worsening with bupropion during cannabis withdrawal, combined with seizure risks, cardiovascular concerns, and lack of safety data for this specific combination, makes concurrent use inadvisable in routine clinical practice. 1, 3